Lenacapavir is the topic of this article. The article talks about using the med to treat HIV+ patients, all of which had multi-drug resistant variants of the virus. This med is new & not completely out to the public yet. It attacks the capsid parts of the virus. This weakens the virus' ability transport, integrate & protect itself. Currently the med is also being researched as a long acting, injectable PrEP measure.
It's a goodread. The 1st version I found was a very jargon heavy abstract that was difficult at best. This is supposed to be a 2 part piece. Give it a read.
Cya...
No comments:
Post a Comment